FDA Inspection 1258252 — UroGen Pharma, Inc.

UroGen Pharma, Inc. — FEI 3017168266

The FDA completed an inspection of UroGen Pharma, Inc. on Dec 16, 2024 in Princeton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Dec 16, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Princeton, NJ (United States)

Additional details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.